State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Screening, Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China.
State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, China.
Cancer Res. 2024 Oct 1;84(19):3132-3140. doi: 10.1158/0008-5472.CAN-24-0642.
Cancer vaccines are an approach to elicit amplified antigen-specific immune responses. Induced pluripotent stem cells (iPSC) have potential utility for the development of universal vaccines because of their intrinsic antigenic epitopes. Concurrently, iPSCs can undergo pluripotent differentiation and are thus a stable source of both antigen-presenting cells for producing immune cell-based vaccines and tumor organoids for facilitating the exploration and adaptive assessment of tumor vaccines. This review describes the specific contributions of iPSCs to vaccine development, summarizes their diverse developmental trajectories, and discusses the obstacles to their application along with potential solutions.
癌症疫苗是一种引发增强型抗原特异性免疫反应的方法。诱导多能干细胞（iPSC）由于其内在的抗原表位，具有用于开发通用疫苗的潜在用途。同时，iPSCs 可以进行多能性分化，因此是产生基于免疫细胞的疫苗的抗原呈递细胞和肿瘤类器官的稳定来源，有助于探索和适应性评估肿瘤疫苗。本综述描述了 iPSC 对疫苗开发的具体贡献，总结了它们的多种发育轨迹，并讨论了它们应用的障碍以及潜在的解决方案。
